Intratumoral administration of CCL21-modified DCs has been shown to promote CD8+T cells and Th1 cells infiltration into the tumor microenvironment of ICI-resistant NSCLC mouse models, while the combination of CCL21-DCs with αPD-1 therapy further enhances antitumor efficacy (115). This evidence concerns the gene CD8A and neoplasm.